Guardant Health (NASDAQ: GH) is a precision oncology company that develops and commercializes blood-based genomic tests used to detect and monitor cancer. Revenue comes primarily from clinical test sales to oncologists and cancer centers, with additional revenue from biopharmaceutical partnerships where drug developers use Guardant's sequencing technology in clinical trials. The company's core products include the Guardant360 liquid biopsy test for advanced cancer profiling and the Shield test for colorectal cancer screening in average-risk adults. Guardant competes in the liquid biopsy and cancer screening markets against both established diagnostics companies and molecular testing specialists. The company is headquartered in Redwood City, California and files annually with the SEC as a well-known seasoned issuer. The filing excerpts available do not support disclosure of specific FY2025 revenue figures, segment breakdowns, customer concentration data, or leadership tenure details, so those are omitted.
Source: SEC 10-K, filed 2026-02-19
Industry: Services-Medical Laboratories Peers: AMN Healthcare Services Inc Option Care Health Inc Chemed Corp CVS Health Corp LHC Group, Inc MSP Recovery Inc Oak Street Health, Inc. Privia Health Group Inc Premier, Inc. Signify Health, Inc.
Loading...